TFRC Protein

Overview

TFRC (Transferrin Receptor 1) is a cell surface receptor that mediates cellular iron uptake through transferrin endocytosis. It plays critical roles in iron homeostasis, cellular metabolism, and has been implicated in various neurodegenerative diseases through its involvement in iron dysregulation and cellular stress responses.^{1Transferrin receptor in iron homeostasis and neurodegenerative disease2015 · Physiological Reviews · PMID 25923040Open reference2Brain iron metabolism and neurodegenerative disorders2011 · Lancet Neurology · PMID 21443567Open reference}

Introduction

Transferrin Receptor 1 (TFRC or TfR1) is a type II transmembrane glycoprotein that facilitates the uptake of transferrin-bound iron into cells. As a key regulator of iron homeostasis, TFRC is essential for normal cellular function and viability. In the brain, TFRC is expressed on neurons, astrocytes, microglia, and endothelial cells of the blood-brain barrier, where it regulates iron entry into the central nervous system.^{3Iron transport across the blood-brain barrier2004 · Annals of the New York Academy of Sciences · PMID 15635456Open reference}

Iron dysregulation is a hallmark of several neurodegenerative diseases, making TFRC an important therapeutic target. The receptor’s role in cellular iron uptake, signal transduction, and protein metabolism provides multiple avenues for intervention in disease processes.

Structure

Transferrin Receptor 1 is a homodimeric protein, with each monomer consisting of:^{4Structure of the human transferrin receptor-transferrin complex2004 · Nature · PMID 14739456Open reference}

• Extracellular domain: The large ectodomain (~660 amino acids) contains the transferrin binding site and is heavily glycosylated

• Transmembrane domain: Single pass (~28 amino acids) anchoring the protein in the plasma membrane

• Cytoplasmic domain: Short intracellular tail (~61 amino acids) containing sorting signals for endocytosis and recycling

The receptor undergoes clathrin-mediated endocytosis and recycling through the endosomal compartment. The extracellular domain is proteolytically cleaved under certain conditions, releasing soluble TFRC (sTfR) that can be detected in blood.

Structural Features

• Monomer molecular weight: ~95 kDa

• Dimerization: Occurs through disulfide bonds in the transmembrane domain

• Iron binding: Each transferrin molecule can bind 2 Fe³⁺ ions; TFRC binds diferric transferrin with high affinity

• pH sensitivity: Binding is pH-dependent, releasing iron in acidic endosomes

Normal Function

TFRC is a cell surface receptor that mediates cellular iron uptake through transferrin endocytosis.^{5Molecular mechanism of iron uptake by transferrin2002 · Cell · PMID 12471176Open reference}

Iron Uptake Pathway

1. Transferrin binding: Diferric transferrin (Fe₂-Tf) binds to TFRC with high affinity (Kd ~10⁻⁹ M)

2. Receptor internalization: The TFRC-Fe₂-Tf complex is internalized via clathrin-coated pits

3. Endosomal acidification: Proton pumps lower endosomal pH, causing iron release from transferrin

4. Iron reduction and transport: STEAP3 reduces Fe³⁺ to Fe²⁺, which is transported into the cytosol by DMT1

5. Receptor recycling: TFRC and apotransferrin return to the cell surface

Cellular Functions

• Iron homeostasis: Primary pathway for cellular iron acquisition

• Cell proliferation: Iron is required for DNA synthesis; TFRC expression correlates with proliferative capacity

• Erythropoiesis: Essential for red blood cell precursor iron uptake

• Brain iron import: Mediates iron entry across the blood-brain barrier via transferrin receptor-mediated endocytosis^{6Transferrin receptor expression in the brain1999 · Journal of Neuroscience Research · PMID 10625781Open reference}

• Cellular metabolism: Supports mitochondrial function and DNA synthesis

• Immune function: Regulates immune cell proliferation and activation

Role in Neurodegeneration

Iron dysregulation is a key pathological feature of multiple neurodegenerative disorders. TFRC plays a complex role in these processes through several mechanisms:^{7TFRC and Alzheimer's disease: Iron dysregulation and therapeutic targeting2017 · Journal of Alzheimer's Disease · PMID 29154824Open reference8Iron and Parkinson's disease: From pathogenesis to treatment2015 · Movement Disorders · PMID 25879066Open reference}

Alzheimer’s Disease

In Alzheimer’s disease, TFRC is involved in:^{9Iron accumulation in Alzheimer's disease2012 · Journal of Alzheimer's Disease · PMID 22385965Open reference}

• Iron accumulation: Elevated iron in AD brain correlates with disease progression

• Amyloid interaction: TFRC may interact with amyloid precursor protein (APP) processing

• Oxidative stress: Iron-induced ROS generation through Fenton chemistry

• Blood-brain barrier: Altered TFRC expression affects brain iron homeostasis

• Tau pathology: Iron can promote tau hyperphosphorylation and aggregation

Parkinson’s Disease

In Parkinson’s disease, TFRC contributes to:^{10Iron in the substantia nigra of Parkinson's disease2002 · Neurology · PMID 12445405Open reference}

• Nigral iron accumulation: Elevated TFRC expression in substantia nigra

• Dopaminergic vulnerability: High iron uptake may increase oxidative stress

• Neuromelanin binding: Iron-loaded neuromelanin can trigger neurodegeneration

• Mitochondrial dysfunction: Iron overload impairs mitochondrial function

• Alpha-synuclein interaction: Iron can accelerate α-synuclein aggregation

Other Neurodegenerative Disorders

• Amyotrophic Lateral Sclerosis (ALS): Altered iron metabolism and TFRC expression in motor neurons^{2Brain iron metabolism and neurodegenerative disorders2011 · Lancet Neurology · PMID 21443567Open reference}0

• Huntington’s Disease: Iron dysregulation contributes to striatal degeneration

• Multiple System Atrophy: Iron accumulation in affected brain regions

• Friedreich’s Ataxia: Primary iron-sulfur cluster deficiency affecting TFRC function

Iron Homeostasis in the Brain

The blood-brain barrier expresses TFRC on endothelial cells, regulating iron entry into the CNS:^{2Brain iron metabolism and neurodegenerative disorders2011 · Lancet Neurology · PMID 21443567Open reference}1

• Transferrin-bound iron crosses via receptor-mediated endocytosis

• Brain iron levels increase with age

• Dysregulation leads to pathological iron accumulation

• Ferroptosis (iron-dependent cell death) is implicated in neurodegeneration

Therapeutic Implications

TFRC represents a therapeutic target for modulating brain iron homeostasis:^{2Brain iron metabolism and neurodegenerative disorders2011 · Lancet Neurology · PMID 21443567Open reference}2

Iron Chelation Therapy

• Deferoxamine: Classic iron chelator; limited brain penetration

• Deferasirox: Oral iron chelator with better CNS access

• Clioquinol: Metal-protein-attenuating compound; shown to reduce brain iron in clinical trials

Receptor-Targeted Approaches

• TFRC agonists: Enhance iron export from cells

• TFRC antagonists: Reduce cellular iron uptake (may be beneficial in iron overload)

• Antibody therapy: Anti-TFRC antibodies to modulate receptor function

Small Molecule Modulators

• Iron-specific chelators: Designed to target brain iron

• Neuroprotective compounds: Antioxidants that mitigate iron-induced damage

• Ferroptosis inhibitors: Liproxstatin-1, ferrostatin-1 under investigation

Biomarker Potential

Soluble TFRC (sTfR) in cerebrospinal fluid and blood has been studied as a biomarker:^{2Brain iron metabolism and neurodegenerative disorders2011 · Lancet Neurology · PMID 21443567Open reference}3

• Reflects cellular iron demand and erythropoietic activity

• Altered levels in neurodegenerative diseases

• Potential for disease diagnosis and progression monitoring

Key Publications

1. Transferrin receptor in iron homeostasis and neurodegeneration. Physiological Reviews (2015).

2. Brain iron metabolism and neurodegenerative disorders. Lancet Neurology (2011).

3. TFRC and Alzheimer’s disease: Iron dysregulation and therapeutic targeting. Journal of Alzheimer’s Disease (2017).

4. Iron and Parkinson’s disease: From pathogenesis to treatment. Movement Disorders (2015).

5. Targeting iron dysregulation in neurodegenerative disease. Nature Reviews Neurology (2020).

See Also

• TFRC Gene — Gene page for transferrin receptor

• Iron Metabolism — Overview of brain iron homeostasis

• Oxidative Stress — ROS in neurodegeneration

• Mitochondrial Dysfunction — Mitochondrial iron handling

• Alzheimer’s Disease — AD overview

• Parkinson’s Disease — PD overview

• Ferroptosis — Iron-dependent cell death

External Links

• UniProt - TFRC

• NCBI Gene - TFRC

• PDB - TFRC Structure

• Human Protein Atlas - TFRC

Background

The study of Tfrc Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.